Browsing Tag
Verve Therapeutics
6 posts
Scribe Therapeutics IPO raises $128.7m as CRISPR biotech prepares to trade as SCTX
Scribe Therapeutics expanded the offering by 20% and priced shares at the top of its range, strengthening its balance sheet before crucial STX-1150 human data expected in 2027.
How VERVE-102 could accelerate the transition from chronic lipid therapy to genomic medicine
Could VERVE-102 shift cholesterol treatment from chronic therapy to one-time gene editing? Explore Eli Lilly and Company’s genomic medicine strategy.
Is gene therapy ready for the heart? TN-201’s pause raises doubts
Find out why the FDA paused Tenaya’s gene therapy for heart disease and what it means for biotech's future in cardiac gene delivery.
Base editing 101: Is precision gene editing safer than CRISPR‑Cas9 for therapeutic use?
Is base editing safer than CRISPR? See how Beam, Verve, and Prime are using non-cutting gene editing to raise the bar for precision and clinical safety.
Lilly to expand into cardiovascular gene editing with Verve Therapeutics acquisition
Eli Lilly’s $1.3B acquisition of Verve Therapeutics targets breakthrough one-time gene therapies for high-risk cardiovascular patients. Read more.
Top 5 PCSK9 inhibitor stocks to watch in 2025: From injectables to gene editing
Explore the top five PCSK9 inhibitor stocks—Amgen, Regeneron–Sanofi, Merck, Novartis, Verve—and what makes each a standout in cholesterol treatment in 2025.